Evommune Q2 FY26 net loss widens to $32.25 million

Reuters2026/08/06 20:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Evommune posted a Q2 net loss of USD 32.25 million, widening from USD 13.57 million a year earlier.
R&D expense rose 34.49% to USD 26.41 million, while G&A expense more than doubled to USD 8.48 million.
Revenue was nil, versus nil in the prior-year quarter.
Cash, cash equivalents and investments totaled USD 288 million at June 30, up from USD 216.7 million at Dec. 31.
Evommune expects EVO756 atopic dermatitis Phase 2b top-line data in September 2026; migraine prophylaxis Phase 2b top-line data is anticipated in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608061605BIZWIRE_USPR_____20260806_BW006411) on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Evommune Q2 FY26 net loss widens to $32.25 million

You may also like

Crypto prices